Back to top
more

Shockwave Medical Inc. (SWAV)

(Delayed Data from NSDQ)

$43.43 USD

43.43
437,633

+2.29 (5.57%)

Updated May 3, 2019 04:00 PM ET

After-Market: $43.32 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain Inari Medical (NARI) Stock Now

by Zacks Equity Research

Inari Medical (NARI) continues to benefit from its commitment toward understanding the venous system. However, dependency on the wide adoption of products is a woe.

Here's Why You Should Retain LHC Group (LHCG) Stock Now

by Zacks Equity Research

LHC Group (LHCG) continues to benefit from strategic deals and a broad array of services.

Here's Why You Should Hold on to DexCom (DXCM) Stock Now

by Zacks Equity Research

DexCom (DXCM) continues to benefit from a solid product portfolio and a strong international presence. However, supply constraints remain a woe.

PerkinElmer's (PKI) Arm Introduces Two CE-Marked Assays

by Zacks Equity Research

PerkinElmer's (PKI) company launches two CE-marked antibody tests that can support the analysis of the immune response to COVID-19.

Here's Why You Should Retain West Pharmaceutical (WST) Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

Is the Options Market Predicting a Spike in Shockwave Medical (SWAV) Stock?

by Zacks Equity Research

Investors need to pay close attention to Shockwave Medical (SWAV) stock based on the movements in the options market lately.

Here's Why You Should Hold on to Stryker (SYK) Stock for Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure weighs on it.

Here's Why You Should Retain Fresenius Medical (FMS) Stock Now

by Zacks Equity Research

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

CONMED (CNMD) to Expand Orthopedic Portfolio With Buyout

by Zacks Equity Research

CONMED's (CNMD) completion of In2Bones Global buyout will expand its orthopedic portfolio.

Earnings Estimates Rising for Shockwave Medical (SWAV): Will It Gain?

by Zacks Equity Research

Shockwave Medical (SWAV) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Shockwave Medical (SWAV) Up 35.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Shockwave Medical (SWAV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Anthem (ANTM) Ties Up to Improve Maternal Health Outcomes

by Zacks Equity Research

Anthem (ANTM) teams up with Happify Health to bring a digital-first solution aimed at addressing issues stemming from the pregnancy experience and other health aspects of women.

Here's Why You Should Retain ShockWave Medical (SWAV) Stock

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D efforts and commitment to clinical studies. However, limited commercial expertise is a woe.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Shockwave Medical's (SWAV) IVL Cleared for Use in China

by Zacks Equity Research

Shockwave Medical's (SWAV) latest regulatory approval is expected to serve a wider patient pool.

Shockwave Medical (SWAV) Beats on Q1 Earnings & Revenues

by Zacks Equity Research

Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and expansion in gross margin.

Shockwave Medical (SWAV) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Shockwave Medical (SWAV) delivered earnings and revenue surprises of 105.26% and 5.74%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

OrthoPediatrics (KIDS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 0% and 3.15%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Shockwave Medical's (SWAV) New Launch to Lower IVL Treatment Time

by Zacks Equity Research

Shockwave Medical's (SWAV) latest global commercial launch is expected to serve a more diverse patient pool.

Here's Why You Should Retain ShockWave Medical (SWAV) Stock

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D efforts and commitment toward clinical studies. However, limited commercial expertise is a woe.

Shockwave Medical (SWAV) is a Top-Ranked Momentum Stock: Should You Buy?

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Shockwave Medical (SWAV) Gains 3.2% Post Q4 Earnings Beat

by Zacks Equity Research

Shockwave Medical's (SWAV) fourth-quarter results reflect robust revenue growth and expansion in gross margin.

Shockwave Medical (SWAV) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Shockwave Medical (SWAV) delivered earnings and revenue surprises of 385.71% and 11.85%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Shockwave Medical (SWAV) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Shockwave Medical (SWAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in Shockwave Medical (SWAV): Can Its 4.5% Jump Turn into More Strength?

by Zacks Equity Research

Shockwave Medical (SWAV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.